We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04526704




Registration number
NCT04526704
Ethics application status
Date submitted
21/08/2020
Date registered
26/08/2020
Date last updated
13/01/2021

Titles & IDs
Public title
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Scientific title
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Secondary ID [1] 0 0
2020-000192-20
Secondary ID [2] 0 0
PL3397-A-U4003
Universal Trial Number (UTN)
Trial acronym
PLX3397
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Tenosynovial Giant Cell Tumor 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bone
Cancer 0 0 0 0
Other cancer types
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pexidartinib

Experimental: Treatment Continuation Cohort - Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.

Experimental: Treatment-Free/Re-Treatment Cohort - Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).


Treatment: Drugs: Pexidartinib
200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of Treatment-Free Participants at 12 Months - This is the proportion of participants who remain treatment-free at Month 12.
Timepoint [1] 0 0
Baseline up to 12 months after last participant enrolled in Cohort
Primary outcome [2] 0 0
Proportion of Treatment-Free Participants at 24 Months - This is the proportion of participants who remain treatment-free at Month 24.
Timepoint [2] 0 0
Baseline up to 24 months after last participant enrolled in Cohort
Secondary outcome [1] 0 0
Change From Baseline in PROMIS Physical Function Scale during the Treatment-Free Period - The PROMIS Physical Function Scale is based on a 5-point rating scale, where 1 is unable to do and 5 is without any difficulty.
Timepoint [1] 0 0
Baseline and then assessed every 3 months until end of study, up to approximately 24 months
Secondary outcome [2] 0 0
Change From Baseline in EQ-5D-5L during the Treatment-Free Period - The EQ-5D-5L questionnaire will ask the participant to describe their health in the areas of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The overall health is rated on a scale from 0 to 100, where 0 is worst health you can imagine and 100 is best health you can imagine.
Timepoint [2] 0 0
Baseline and then assessed every 3 months until end of study, up to approximately 24 months
Secondary outcome [3] 0 0
Number of Participants Who Reported Treatment-Emergent Adverse Events (TEAEs) during the Treatment-free Period - TEAEs are defined as new Adverse Events or pre-existing conditions that worsen in CTCAE grade after the first dose of study drug and up to 30 days after last dose of study drug.
Timepoint [3] 0 0
Baseline up to 30 days after the start of re-treatment or end of study (whichever occurs first), up to approximately 24 months
Secondary outcome [4] 0 0
Percentage of Participants Achieving Tumor Response as assessed by Magnetic Resonance Imaging (MRI) - Individual participant outcomes by tumor volume score (TVS) will be classified according to the following criteria via RECIST: Complete response (CR), Lesion completely gone; Partial response (PR), =50% decrease in volume score relative to baseline; Progressive disease (PD), =30% increase in volume relative to lowest score during the study whether at baseline or some other visit; Stable disease (SD), Does not meet any of the prior criteria based on score during study.
Timepoint [4] 0 0
Baseline and assessed every 6 months (treatment continuation) or every 3 months (treatment-free/re-treatment), up to approximately 24 months
Secondary outcome [5] 0 0
Number of Participants Who Reported TEAEs during the Re-treatment Period - TEAEs are defined as new Adverse Events or pre-existing conditions that worsen in CTCAE grade after the first dose of study drug and up to 30 days after last dose of study drug.
Timepoint [5] 0 0
Start of re-treatment up to 30 days after end of study, up to approximately 24 months

Eligibility
Key inclusion criteria
- Currently enrolled and on pexidartinib treatment in one of the following studies:
Study PLX108-10 (ENLIVEN), Study PLX108-01, Study PL3397-A-A103 or Study
PL3397-A-U126.

- Willing and able to complete the PROMIS Physical Function Scale and EQ-5D-5L
throughout the study.

- Willing and able to provide written informed consent prior to any study-related
procedures and to comply with all study requirements.

- Females of reproductive potential must have a negative urine pregnancy test at
Screening/Baseline (to be confirmed by a serum pregnancy test taken on the last
treatment visit of their prior study). They are advised to use an effective,
non-hormonal method of contraception during treatment with pexidartinib and for 1
month after the last dose. Males with female partners of reproductive potential should
be advised to use an effective method of contraception during treatment with
pexidartinib and for 1 month after the last dose. Female partners of male patients
should concurrently use effective contraceptive methods (hormonal or non-hormonal).

Note: A female is considered of reproductive potential following menarche and until
becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently
sterile (undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) with
a confirmed by follicle stimulating hormone (FSH) test level >40 mIU/mL.

- Male participants must not freeze or donate sperm starting at Screening and throughout
the study period, and for at least 5 half-lives or 1 month after the final study drug
administration, whichever is longer. Female participants must not donate, or retrieve
for their own use, ova from the time of Screening and throughout the study treatment
period, and for at least 1 month or 5 half-lives after the final study drug
administration, whichever is longer.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participant has a clinically significant abnormality identified by the Investigator at
Screening on physical examination, laboratory tests, or electrocardiogram (ECG) which,
in the judgement of the Investigator, would preclude the participant's safe completion
of the study.

- Exposure to another investigational drug or current participation in other therapeutic
investigational procedures, besides pexidartinib studies, within 1 month prior to
start of study treatment. Any known contraindication to treatment with, including
hypersensitivity to, the study drug(s) or excipients in pexidartinib.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
Peter MacCallum Cancer Centre - East Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3000 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Oregon
Country [7] 0 0
Hungary
State/province [7] 0 0
Budapest
Country [8] 0 0
Italy
State/province [8] 0 0
Bologna
Country [9] 0 0
Italy
State/province [9] 0 0
Milano
Country [10] 0 0
Netherlands
State/province [10] 0 0
Leiden
Country [11] 0 0
Spain
State/province [11] 0 0
Barcelona
Country [12] 0 0
Spain
State/province [12] 0 0
Sevilla
Country [13] 0 0
Taiwan
State/province [13] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Daiichi Sankyo, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy
in previously treated participants with tenosynovial giant cell tumor (TGCT).
Trial website
https://clinicaltrials.gov/show/NCT04526704
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Team Leader
Address 0 0
Daiichi Sankyo, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
(US sites) Daiichi Sankyo Contact for Clinical Trial Information
Address 0 0
Country 0 0
Phone 0 0
908-992-6400
Fax 0 0
Email 0 0
CTRinfo@dsi.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04526704